Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GEMCITABINE Cause Thrombotic microangiopathy? 648 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 648 reports of Thrombotic microangiopathy have been filed in association with GEMCITABINE (Gemcitabine). This represents 2.1% of all adverse event reports for GEMCITABINE.

648
Reports of Thrombotic microangiopathy with GEMCITABINE
2.1%
of all GEMCITABINE reports
102
Deaths
351
Hospitalizations

How Dangerous Is Thrombotic microangiopathy From GEMCITABINE?

Of the 648 reports, 102 (15.7%) resulted in death, 351 (54.2%) required hospitalization, and 121 (18.7%) were considered life-threatening.

Is Thrombotic microangiopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GEMCITABINE. However, 648 reports have been filed with the FAERS database.

What Other Side Effects Does GEMCITABINE Cause?

Off label use (3,319) Disease progression (3,123) Thrombocytopenia (2,320) Drug ineffective (2,003) Malignant neoplasm progression (1,962) Neutropenia (1,892) Anaemia (1,745) Pyrexia (1,511) Nausea (1,336) Myelosuppression (1,197)

What Other Drugs Cause Thrombotic microangiopathy?

TACROLIMUS (1,982) MYCOPHENOLATE MOFETIL (820) CYCLOSPORINE (724) ECULIZUMAB (636) CYCLOPHOSPHAMIDE (602) FLUDARABINE (480) METHOTREXATE (447) CARFILZOMIB (350) METHYLPREDNISOLONE (345) MELPHALAN (332)

Which GEMCITABINE Alternatives Have Lower Thrombotic microangiopathy Risk?

GEMCITABINE vs GEMCITABINE\GEMCITABINE GEMCITABINE vs GEMFIBROZIL GEMCITABINE vs GEMTUZUMAB OZOGAMICIN GEMCITABINE vs GEMZAR GEMCITABINE vs GENTAMICIN

Related Pages

GEMCITABINE Full Profile All Thrombotic microangiopathy Reports All Drugs Causing Thrombotic microangiopathy GEMCITABINE Demographics